October 2025

Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair

Business Wire India Neuraptive Therapeutics, Inc., a biotechnology company focused on developing novel therapies to improve outcomes in peripheral nerve injuries (PNI), today announced the first patient has been enrolled…